
|Articles|January 4, 2016
KaloBios Files for Bankruptcy Following Shkreli Arrest
January 04, 2016.
Advertisement
Following the arrest on December 17 of former CEO Martin Shkreli, KaloBios Pharmaceuticals (South San Francisco, CA) filed for bankruptcy last week. According to Bloomberg Business, the company plans to use the bankruptcy to buy time to implement its restructuring plans. Shkreli, who took charge of KaloBios just a month ago, was arrested on fraud charges related to his position at his former company, Retrophin. KaloBios fired the controversial CEO shortly after his arrest. http://www.bloomberg.com/news/articles/2015-12-30/shkreli-s-former-biotech-company-kalobios-files-for-bankruptcy-iisup3fw
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Changing Reality of Pharmaceutical Commercialization in a Cold Chain-Driven Market
2
Vertex to Acquire Crinetics Pharmaceuticals for $10 Billion
3
Reshoring Pharma and Biotech Manufacturing Ahead of This Summer’s Tariff Deadlines: Q&A with Ryan Last
4
Catalent Announces Expanded Partnership with Nanoscope Therapeutics
5




